Uncategorized

We welcome our new colleague Sara del Palacio to the team!

Inhibitec Antibodies has been one of the startups selected in the ‘Programa Personal Tecnico I+D’ supported by Sociedad para el Desarrollo Regional de Cantabria (SODERCAN) to expand its scientific team with the addition of an R&D technician (RH23-XX-025). We greatly appreciate the support of SODERCAN for Inhibitec since the beginning of our project. https://boc.cantabria.es/boces/verAnuncioAction.do?idAnuBlob=386579

We welcome our new colleague Sara del Palacio to the team! Read More »

BIOSPAIN Congress (26-28th September 2023)

Inhibitec’ s team had the privilege to participate in BIOSPAIN 2023, one of the main international biotechnology events in southern Europe, held in Barcelona. This was a dynamic conference marked by numerous meetings we had which offered the great opportunity to share our innovative therapy for Psoriatic Arthritis with potential investors and collaborators. This platform

BIOSPAIN Congress (26-28th September 2023) Read More »

Inhibitec Anticuerpos is selected by the NEOTEC 2021 Grant (SNEO- 2021 1187). ‘CDTI Supported/ Subvencionado por CDTI’

Towards a novel disruptive therapy in autoimmune disease We are thrilled to announce that Inhibitec has been selected as a recipient of the NEOTEC 2021 grant provided by CDTI (Center for Industrial Technological Development) with the support of the Ministerio de Ciencia e Innovación. This prestigious grant is designed to impulse new entrepreneurial projects that

Inhibitec Anticuerpos is selected by the NEOTEC 2021 Grant (SNEO- 2021 1187). ‘CDTI Supported/ Subvencionado por CDTI’ Read More »

Inhibitec Antibodies, S.L. Cantabrian biotechnology company

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.  A significant number of psoriatic patients with severe disease do not respond to existing therapies.

Inhibitec Antibodies, S.L. Cantabrian biotechnology company Read More »

Scroll to Top